April 5 (Reuters) - Theramex said on Friday it was

considering concerns raised by Britain's competition watchdog's

phase 1 probe over the company's purchase of European rights to

two of U.S. drugmaker Viatris' ( VTRS ) women's healthcare

products ranges.

The company in a statement to Reuters said the regulator's

decision is a normal step in the merger review process and will

not have an impact on its ability to supply existing hormone

replacement therapies (HRT) products in the UK.

The Competition and Markets Authority (CMA) had said a day

before that the deal could lead to higher prices and fewer

options for HRT, as Theramex is one of the largest suppliers in

the HRT market in the UK.

The regulator said both parties have five working days to

respond before the deal is put through a phase 2 investigation.